Stroke

An analysis of data from more than 30k patients with DVT from the RIETE registry is providing clinicians with new insight into the difference in presentation and outcomes among patients with isolated distal DVT and proximal DVT.

An analysis of data from a single center in Switzerland from a 15-year period details the prevalence of undiagnosed major risk factors among patients admitted with acute ischemic stroke, suggesting 67.7% present with at least 1 undiagnosed risk factor.

Dr. Gregory Weiss provides perspective on a recent study detailing the risks of thrombosis observed with different COVID-19 vaccines among patients from a group of countries in Europe.

A post hoc analysis of the AUGUSTUS trial provides an overview of the effects of various antithrombotic regimens after ACS or PCI in patients with AFib and a history of stroke, TIA, or thromboembolism.

An analysis of national data from Sweden suggests men with prostate cancer were at a 48% greater risk of deep vein thrombosis and a 47% greater risk of pulmonary embolism compared to their counterparts without prostate cancer.

Published on May 17, the 2022 AHA/ASA guidelines for the management of intracerebral hemorrhage were created with the intent of replacing 2015 guidance with updated evidence-based recommendations.

A study from HRS 2022 suggests Black patients with AFib were 25% less likely to be on oral anticoagulants at hospital discharge compared to their White counterparts those discharged 18% less likely to receive DOACs than their White counterparts.

Data show 15-mg edoxaban dose was superior to placebo in preventing stroke or systemic embolism in all 3 age strata studied, with higher incidence of major bleeding.

After adjustment for age and sex, data show the reduction in mortality rates in the patients receiving dialysis was greater than the general population.

An analysis of data from more than 110k hospitalized patients with COVID-19 suggests aspirin use on the first day of hospitalization was linked to lower odds for both in-hospital mortality and pulmonary embolism in weighted analyses.

Greater increases were observed among members of racial and ethnic minority groups, with the highest increase among non-Hispanic Black individuals.

Released on March 21, the practice advisory from the American Academy of Neurology advocates for a management approach focused on optimization of medical therapies and exercise over stenting for reducing risk of recurrent events and death in patients with symptomatic intracranial atherosclerotic arterial stenosis

An analysis of data from a prospective stroke registry suggests presence of hypertriglyceridemia was associated with a more than 2-fold increase in risk of MACE among patients with a history of acute stroke or TIA, even with adjustment for baseline LDL-C and statin use.

A new study suggests use of apixaban was associated with a lower rate of rehospitalization for VTE compared with warfarin in patients with VTE requiring extended anticoagulation.

Data show the absolute risk reductions of treatment with statins in terms of all-cause mortality, myocardial infarction, and stroke are modest compared with the relative risk reductions.

Data from Medicare beneficiaries provide insight into the risk of stroke associated with a diagnosis of COVID-19 among older adults, which results suggest peaks within the first 3 days of diagnosis.

A retrospective analysis of 10 years of stroke admissions suggests pediatric stroke patients with LVO who did not undergo thrombectomy were at 6 times greater risk of moderate to severe disability or death than those who underwent thrombectomy.

A retrospective chart review from ISC 2022 details the safety and efficacy of low-dose ticagrelor in clopidogrel-resistant neuroendovascular patients.

An international, retrospective analysis presented at ISC 2022 provides evidence suggesting use of DOACs as a treatment for cerebral venous thrombosis was associated with similar risk of recurrent clots and death as warfarin, but a 65% lower risk of major bleeding.

A meta-analysis presented at ISC 2022 suggests the risk of in-hospital mortality for stroke-related admissions was 42% greater among patients hospitalized during the pandemic compared to prepandemic.

On the first day of International Stroke Conference 2022, the AHA released a scientific statement outlining strategies to optimize in-hospital stroke care.

Analysis of real-world registry data presented at ISC 2022 provide insight into the risk of intracranial hemorrhage with tenecteplase versus alteplase in patients with acute ischemic stroke.

A positive CDI test was more common in patients with suffered an aneurysmal subarachnoid hemorrhage than it was in patients with intracerebral hemorrhage or ischemic stroke.

Bentracimab achieved the predetermined primary endpoint of immediate and sustained reversal of the antiplatelet effects of ticagrelor in the REVERSE-IT trial.

Treatment with statins, nitrates, dihydropyridines, verapamil, and proton-pump inhibitors were predictors of death or ischemic events for patients in the HGFR group.